Assessment and Interpretation of Bioequivalence for Two Drug Formulations using Crossover Design

  • Published : 1999.08.01

Abstract

Crossover design is officially except for special occasions recommended by KFDA and FDA for assessing Bioequivalence between two drugs one for reference and the other for innovator. Such design is regarded as a special case of latin square split-polt or repeated measurement design and its main difference with other designing methods is that each subject in an experiment is exposed two drugs in sequence. Therefore general statistical analysis is not suitable since the model for this experiment includes carryover effect in addition to period and sequence effect. in this paper analysis for crossover model with two drugs and its interpretation are mainly discussed and an example is given for illustration.

Keywords

References

  1. 생물학적 동등성 기준 식품의약안전청
  2. 응용통계연구 v.12 no.1 두개의 제제 형식과 기존 제제간의 생물학적 동등성 검증 오현숙;고승곤;김정일;박상규
  3. American Statistician v.45 A simple approach for finding estimable functions in linear models Elswick, R.K.;Gennings, C.;Chinchilli, V.M.;Dawson, K.S.
  4. Federal Register v.42 no.5 FDA
  5. Biometrics v.21 The two-period changeover design and its use in clinical trials Grizle, J.E.
  6. British Journal of Clinical Pharmacology v.8 The two-period cross-over clinical trial Hills, M.;Armitage, P.
  7. Comm. Stat. - Theory and Meth. v.21 no.9 On the assessment of variability in bioavailability/bioequivalance studies Liu, J.P.;Chow, S.C.